-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-9401 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-9401 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-9401 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Solid Tumor Drug Details: ONC-392 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aumolertinib Mesylate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aumolertinib Mesylate in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aumolertinib Mesylate in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Non-Small Cell Lung Cancer Drug Details: ONC-392...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Wegovy in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Wegovy in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Wegovy in Diastolic Heart Failure (HFpEF) Drug Details: Semaglutide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Odevixibat in Biliary Atresia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Odevixibat in Biliary Atresia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Odevixibat in Biliary Atresia Drug Details: Odevixibat Sesquihydrate (Bylvay) is acts...
-
Company Insights
NewLifeward Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Lifeward Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Lifeward Inc (Lifeward), formerly ReWalk Robotics Ltd, is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include rewalk personal systems and ReWalk rehabilitation. Lifeward's rewalk personal system is a battery-powered system that controls movement using subtle changes in...
-
Sector Analysis
NewThe Masters Golf Tournment, 2024 – Post Event Analysis
The Masters Golf Tournament 2024 Post Event Analysis Report Overview The estimated annual sponsorship revenue for the Masters Golf Tournament 2024 is $50.75 million. The 2024 Masters Tournament was the 88th edition of the Masters Tournament and the first of the men’s four major golf championships held in 2024. Tickets for the tournament are sold through a lottery system and therefore tickets on the round of initial sale are very hard to get. Once the lottery process finishes, tickets are...